Pfizer Buys InnoPharma As It Buffs Up Established Pharma Unit
This article was originally published in The Pink Sheet Daily
The big pharma will acquire privately held InnoPharma for $225 million upfront for its rich pipeline of generic injectables and ophthalmic products.
You may also be interested in...
A Pfizer break up is still an option even if the company completes a mega-merger with AstraZeneca, CEO Ian Read said May 5. The company’s first quarter sales and earnings results highlighted how important completing a transaction could be for the company, with sales down 9% and earnings down 15%.
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.